Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 01, 2021 07:30 ET | Source: Spark Therapeutics, Inc.

Spark Therapeutics Announces First Participant Dosed in Phase 1/2 Study of Investigational Gene Therapy for Late-Onset Pompe Disease

First participant dosed in the RESOLUTESM trial, a Phase 1/2 dose-escalation study of SPK-3006 Enrollment of approximately 20 total study participants is ongoing PHILADELPHIA, Feb. 01, 2021 (GLOBE...
November 16, 2020 07:30 ET | Source: Spark Therapeutics, Inc.

Spark Therapeutics Expands Visionary Leadership with Appointment of Michael Retterath as Chief Strategy Officer

PHILADELPHIA, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Spark Therapeutics, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and a fully integrated, commercial gene therapy company dedicated to...
August 10, 2020 07:30 ET | Source: Spark Therapeutics, Inc.

Spark Therapeutics Deepens Drug Development Expertise in Hematology and Rare Disease with Appointment of Gallia G. Levy, M.D., Ph.D., as Chief Medical Officer

PHILADELPHIA, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Spark Therapeutics, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and a fully integrated, commercial gene therapy company dedicated to...
August 03, 2020 07:30 ET | Source: Spark Therapeutics, Inc.

Spark Therapeutics Recognized for Fourth-straight Year as One of Philadelphia’s “Best Places to Work” by the Philadelphia Business Journal

PHILADELPHIA, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Spark Therapeutics, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and a fully integrated, commercial gene therapy company dedicated to...
July 12, 2020 10:15 ET | Source: Spark Therapeutics, Inc.

Spark Therapeutics Announces Updated Data on SPK-8011 from Phase 1/2 Clinical Trial in Hemophilia A at ISTH 2020 Virtual Congress

All five participants in the 5x1011 vg/kg and 1×1012 vg/kg dose cohorts and seven participants in the 2×1012 vg/kg dose show an acceptable safety profile, stable and durable factor VIII expression and...
June 01, 2020 11:00 ET | Source: Spark Therapeutics, Inc.

Study Demonstrating Role of IdeS in Enabling of Gene Therapy in the Presence of Neutralizing Anti-AAV Antibodies Published in Nature Medicine

PHILADELPHIA, June 01, 2020 (GLOBE NEWSWIRE) -- Spark Therapeutics, a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, today announced...
October 25, 2019 09:54 ET | Source: Spark Therapeutics, Inc.

Spark Therapeutics Wins Prix Galien USA Award for LUXTURNA® (voretigene neparvovec-rzyl) as Best Biotechnology Product

PHILADELPHIA, Oct. 25, 2019 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease,...
September 18, 2019 07:30 ET | Source: Spark Therapeutics, Inc.

Paralympic Skier Danelle Umstead Teams Up with Spark Therapeutics to Help People Living with Inherited Retinal Diseases (IRDs) Access Genetic Testing

Paralympic, blind skier declared Eye Want 2 Know® and pursued genetic testing to uncover the genetic cause of her retinitis pigmentosa (RP), an IRD Spark Therapeutics unveils enhanced ID YOUR IRD®...
August 27, 2019 07:30 ET | Source: Spark Therapeutics, Inc.

Spark Therapeutics Announces Change of Location for Annual Meeting of Stockholders

PHILADELPHIA, Aug. 27, 2019 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully-integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease,...
April 17, 2019 07:30 ET | Source: Spark Therapeutics, Inc.

Spark Therapeutics Announces Sponsorship of Believe Limited’s First-Ever Science Fair for the Hemophilia Community at 2019 National Hemophilia Foundation’s Bleeding Disorders Conference

PHILADELPHIA, April 17, 2019 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ: ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease,...